Contribution: Industrial Research Assistance Program – Contributions to Firms
Vital Biosciences Inc
$450,000.00
COVID-19 High-capacity and Rapid Serological Testing
FY 2020-21 · 2020-06-01
Summary
To quantify the strength and nature of the immune response to COVID-19 infection after recovery, the proposed serological tests will measure SARS-CoV-2-reactive IgG and IgM antibodies by rapidly adapting a next-generation immunoassay. By the end of the proposed project, all clinical validation tests required by Health Canada for expedited approval will be complete.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Mississauga|Mississauga, Ontario, Canada
Recipient Type
For-profit organization
Business Number
738751494
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2020-06-01 | 2020-21 | $450,000.00 |
| 2 | 2020-06-01 | 2020-21 | $450,000.00 |
As published
Additional Information
This agreement has been amended 2 time(s). The end date of this agreements has been modified by 90 days.
Additional Information (French)
Cet accord a été modifié 2 fois La date de fin du présent accord a été changé de 90 jours.
Agreement End Date
2021-02-28
Agreement Number
951901
Agreement Start Date
2020-06-01
Agreement Title
COVID-19 High-capacity and Rapid Serological Testing
Agreement Title (French)
COVID-19 - Tests sérologiques rapides et de grande capacité
Agreement Type
Contribution
Agreement Value
$450,000.00
Amendment Date
2020-12-11
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
To quantify the strength and nature of the immune response to COVID-19 infection after recovery, the proposed serological tests will measure SARS-CoV-2-reactive IgG and IgM antibodies by rapidly adapting a next-generation immunoassay. By the end of the proposed project, all clinical validation tests required by Health Canada for expedited approval will be complete.
Description (French)
Afin de quantifier l'intensité et la nature de la réponse immunitaire à l'infection par la COVID-19 après la guérison, les tests sérologiques proposés mesureront les anticorps IgG et IgM réactifs au CoV-2 du SRAS en adaptant rapidement un immuno-essai de nouvelle génération. À la fin du projet proposé, tous les tests de validation clinique requis par Santé Canada pour une approbation accélérée seront terminés.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Mississauga--Erin Mills
Federal Riding (French)
Mississauga--Erin Mills
Federal Riding Number
35060
NAICS Code
334512
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
738751494
Recipient City
Mississauga|Mississauga
Recipient Country
CA
Recipient Legal Name
Vital Biosciences Inc
Recipient Postal Code
L5L 4L4
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2020-2021-Q1-951901
